Abstract:Objective: Mutations in driver genes contribute to the development and progression of lung adenocarcinoma (LUAD). However, in the dynamic evolutionary process from adenocarcinoma in situ (AIS) to minimally invasive adenocarcinoma (MIA) and eventually to invasive adenocarcinoma (IAC), the role of driver genes is currently unclear. This study aimed to analyse the role of driver gene status in the progression of LUAD from preneoplasia to IAC.Methods: Patients with LUAD who underwent surgery in our centre from March 2015 to December 2019 were retrospectively analysed, and LUAD patients with tumour sizes ≤3.0 cm and pN0 were included in the final analysis. The mutation status of common driver genes, including EGFR, ALK and ROS1, was detected. According to the pathological characteristics, the patients were divided into three stages: AIS, MIA and IAC. We analysed the distribution of driver gene mutation frequencies across three stages of LUAD. In addition, we performed univariate and multivariate analyses of IAC patients to screen for relevant variables (driver genes and clinicopathological features) affecting their prognosis.Results: Ultimately, 759 patients with LUAD were enrolled, including 135, 130, and 494 cases of AIS, MIA, and IAC, respectively. EGFR mutations were identified in 359 (61.8%) patients, and with the transition from AIS to MIA, the frequency of EGFR mutations increased from 33.3% to 50.8%, P=0.004, whereas the frequency of EGFR mutations was comparable for MIA and IAC (50.8% vs. 50.2%, P=0.922). Moreover, ALK and ROS1 gene fusions were identified in 17 cases (2.2%) and 2 cases (3.0‰) respectively. For AIS, neither ALK gene nor ROS1 gene fusions were observed. When the tumour progressed to MIA, the ALK fusion frequency was 2.3% (3/130), which was basically consistent with the ALK fusion frequency of 2.8% in IAC, P=0.143. For IAC, fusions of ROS1 fell into this category. In addition, we found that 40 patients (5.3%) developed metastasis/recurrence, and 14 patients (1.8%) died of cancer-specific related diseases. Notably, for AIS, there were no recurrences and no deaths, and for MIA, only 1 patient died with LUAD. Finally, survival analysis was performed in patients with IAC, and EGFR-mutant patients showed better DFS than EGFR-wild-type patients (P=0.036). Conversely, patients with ALK fusions showed worse DFS than those with ALK wild-type (P=0.004), and the same results were found in OS analysis.Conclusions: The accumulation of EGFR driver gene mutation frequencies mediates the progression of LUAD from AIS to MIA. When the tumour progresses to IAC, multivariate analysis based on driver gene status can be used as a pivotal prognostic factor.Funding Information: This study was funded by the Discipline Innovation Development Plan Project of Tangdu Hospital (2021LCYJ005), National Natural Science Foundation of China (82002421), and Special Fund for Elite Talents of Shaanxi Provincial People's Hospital(2021JY-20).Declaration of Interests: We declare that we have no conflicts of interest.Ethics Approval Statement: This study was approved by the Ethics Committee of Fourth Military Medical University Affiliated Tangdu Hospital (K202107-19), and all recruited patients signed an informed consent form.

[Advances on driver oncogenes of lung adenocarcinoma].

[Advances of the Role of Lung Cancer Driver Gene and PD-1/PD-L1 Pathway Interaction in the Tumorigenesis and Progression of Non-small Cell Lung Cancer].

Correlation Analysis Between Driver Gene Mutation and Clinicopathological Features in Lung Adenocarcinoma Based on Real-World Cumulative Clinical Data

Epidermal Growth Factor Receptor Mutations Detected in Tumors from Chinese “never Smokers”with Lung Adenocarcinoma

Prediction of Potential Drivers Connecting Different Dysfunctional Levels in Lung Adenocarcinoma Via a Protein–protein Interaction Network

Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention

Oncogenic alterations in advanced NSCLC: a molecular super-highway

Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study

Driver Genes in Non-Small Cell Lung Cancer: Characteristics, Detection Methods, and Targeted Therapies

Genomic Profiling of Driver Gene Mutations in Chinese Patients with Non-Small Cell Lung Cancer

A Genome-Wide Comprehensive Analysis of Alterations in Driver Genes in Non-Small-cell Lung Cancer

Identification of Genes Associated with Lung Adenocarcinoma Prognosis

Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion

Genomic and Transcriptomic Dynamics in the Stepwise Progression of Lung Adenocarcinoma

A Novel Acquired EGFR-SEPT14 Fusion Confers Differential Drug Resistance to EGFR Inhibitors in Lung Adenocarcinoma.

Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers

Concomitant Pathogenic Mutations and Fusions of Driver Oncogenes in Tumors

Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer

Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy

Analysis of Major Known Driver Mutations and Prognosis in Resected Adenosquamous Lung Carcinomas

Dynamic Contribution of EGFR Mutation Status in Lung Adenocarcinoma from in Situ to Invasive Adenocarcinoma: A High-Volume Retrospective Study